Executive summary
US Drug Patent 11,896,586 claims an apixaban-layered treated core made by spray-layering apixaban plus a polymer carrier on a particulate substrate (e.g., sugar beads or MCC/lactose/mannitol) to form a surface layer at very low apixaban loading (about 0.001% to 0.20% w/w). It adds process limitations (spray-layered dispersion; and in dependent independent claim language, a solvent concentration below the apixaban solubility limit). It then covers multi-core formulations, including capsule dosage forms (notably sprinkle capsules) and methods of treating thromboembolic disorders by dispersing/dissolving the treated cores in a liquid vehicle (including food or beverage) and administering to a subject (including neonates).
Below is a structured claim-by-claim scope and a business-oriented patent landscape read that shows what design-arounds are plausible and what competitor entry paths are blocked by claim elements.
US Patent 11,896,586 claim scope: what is protected by the apixaban “treated core” layer?
Core protected subject matter
The patent’s center of gravity is a particulate “treated core” where:
- there is a core substrate (bead/sphere or particle),
- the core substrate has a surface layer containing apixaban + carrier,
- the core contains about 0.001% w/w to about 0.20% w/w apixaban,
- the layer is formed on the surface of the core substrate.
This structure targets spray-coated micro-dosing of apixaban onto excipient particles intended for dispersion in a liquid (including food/beverage) and/or sprinkle capsule administration.
Claim 1: baseline treated core parameters
Claim 1 fixes the minimum scope:
- Treated core comprising:
- core substrate
- apixaban and a carrier on the core substrate
- apixaban loading 0.001% to 0.20% w/w
- layer formed on surface of the core substrate
Implication for infringement design
A product likely falls within Claim 1 if it uses any particulate excipient as a core, applies apixaban with a carrier as a surface layer, and lands within the stated apixaban loading band.
Claim 2: process refinement (spray-layered dispersion)
Claim 2 adds that apixaban + carrier are applied by spray-layered dispersion.
Implication
This narrows method-of-manufacture scope for any process claim that depends on spray-layering. A non-spray application route (e.g., melt coating, solvent evaporation from a different coating mode, dry blending, adsorption-only without spray layering) may still infringe Claim 1 if it results in the same structure, but it can affect enforceability depending on how product claims vs process claims are asserted.
Claims 3-5: allowable core substrates
- Claim 3 lists acceptable core substrates:
- sugar bead/sphere
- or microcrystalline cellulose, lactose, mannitol particles
- Claim 4 narrows to sugar beads/spheres.
- Claim 5 defines sugar bead composition examples: sugar syrup, corn starch, sucrose.
Implication
Competitors using alternative inert cores (e.g., different sugar alcohol beads or different polymer beads) may avoid this explicit list if a court construes “core substrate” narrowly to the recited types, but Claim 1 is drafted broadly (“a core substrate”) and could be argued to include equivalents.
Claim 6: allowable carrier polymer
Claim 6 constrains “carrier” to hydroxypropylcellulose and/or hypromellose (HPMC/Hypromellose).
Implication
This is a meaningful lever for design-around: carriers outside HPMC/hypromellose (e.g., PVP/VA, Eudragit, PEG-based binders, ethylcellulose, acrylate polymers) can be used to argue non-infringement of dependent claim scope. Claim 1, however, does not require HPMC unless a dependent claim is asserted.
Claim 7: core size band
Claim 7 limits core size to 150 to 355 microns.
Implication
Particle engineering can be a non-trivial defense. If a competitor uses smaller/larger pellets, it may avoid dependent claim scope tied to this band.
US Patent 11,896,586 formulation claims: what capsules, sprinkle formats, and dose strengths are covered?
Claim 8: formulations comprising at least one treated core
Claim 8 covers a formulation including at least one treated core of Claim 1.
This is the structural bridge from the particulate technology to dosage forms.
Claims 9-12: numeric formulation composition windows
These dependent claims tighten apixaban and component percentages:
- Apixaban: 0.09% to 0.11% w/w (Claim 9) and also “about 0.1% w/w” (Claim 12)
- Carrier content: 9% to 11% w/w (Claim 10)
- Core substrate content: 89% to 91% w/w (Claim 11)
Implication
A competitor that changes formulation percentages can step outside dependent claim windows while still potentially infringing broader Claim 8 (if “at least one treated core” is used and the treated core itself falls within Claim 1).
Claims 13-16: capsule dosage forms
- Claim 13: formulation in a capsule
- Claim 14: capsule is gelatin or HPMC capsule
- Claim 15: capsule is a sprinkle capsule
- Claim 16: capsule comprises about 0.1 mg apixaban
Implication
This is the most direct commercial-use coverage. Sprinkle dosing is a distinct use case (pediatrics, neonates, patients who cannot swallow whole tablets). A competitor selling a different presentation (e.g., sachets, oral solution, tablet, hard cap with different fill units) may still be exposed under broader claims but can avoid the sprinkle-capsule-dependent limitations.
Claims 20-27: dose range mapping
Claims 20-27 define formulations comprising roughly:
- apixaban 0.1 to 0.4 mg (Claim 20)
- and specific unit doses: 0.1, 0.2, 0.3, 0.4 mg (Claims 24-27)
They repeat component percentage dependencies tied to ~0.1% w/w style compositions.
Implication
These are concrete product targets. If a competitor targets different strengths (e.g., 0.05 mg or 0.5 mg per sprinkle unit) it can evade these dependent claims, but not necessarily the base treated-core claims.
US Patent 11,896,586 method claims: what administration modes are protected?
Claim 17: treating by dispersing/dissolving in a liquid carrier
Claim 17 covers:
- dispersing and/or dissolving the treated core in a liquid carrier
- administering the liquid carrier to a subject
- for treating a thromboembolic disorder
Claims 18-19: food/beverage vehicle; neonates
- Claim 18: liquid carrier is a food or beverage
- Claim 19: subject is a neonate
Implication
This supports a litigation strategy focused on intended use and administration instructions that accompany the product. If a competitor sells similar treated cores but markets with different instructions (not dispersing/dissolving, or not for neonates), they can still be challenged, but the method claim fit is often easier to litigate where the label explicitly instructs the covered method.
US Patent 11,896,586 “solubility limit” process limitation: what does Claim 30 change?
Claim 30: treated core with spray process constrained by solubility
Claim 30 repeats Claim 1’s treated core structure and introduces a process constraint:
- apixaban 0.001% to 0.20% w/w
- apixaban + carrier in a layer on the surface
- applied by spray-layered dispersion process
- carried out with a concentration of apixaban in a solvent below a solubility limit
Key difference
Even where spray coating is already part of dependent claim language (Claim 2), Claim 30 adds a solubility-limit operational window. That can distinguish manufacturing methods that might otherwise be similar.
Claims 31-32: core substrates and size again
- Claim 31 repeats the core substrate list (sugar bead/sphere, MCC, lactose, mannitol)
- Claim 32 repeats core size 150-355 microns
Claims 33-45: formulation and sprinkle capsule dependencies tied to Claim 30
Claims 33-45 mirror Claims 8-16 and add the Claim 30 process basis to formulation and administration scope.
Implication
If a competitor uses different solvent concentration regimes (solubility-limited vs not), that can be a litigation hinge, particularly if patents are asserted as manufacturing-related limitations tied to the product’s formed layer.
Claim coverage map: which elements create infringement friction?
| Claim element |
Where it shows up |
Why it matters for infringement |
| Apixaban-layered treated core (0.001% to 0.20% w/w) |
Claim 1, 30 |
Main structural hook; hard to avoid if product uses same loading. |
| “Layer formed on surface” |
Claim 1, 30 |
Drives whether apixaban is bound throughout vs coated on surface. |
| Spray-layered dispersion |
Claim 2, 30 |
Targets manufacturing route; helps narrow if product can be shown identical in structure but made differently. |
| Core substrate type list (sugar bead/sphere; MCC/lactose/mannitol) |
Claim 3, 4, 31 |
Dependent limitation; can be used for non-infringement if cores differ and construction is narrow. |
| Carrier = HPMC/Hypromellose |
Claim 6 |
Another dependent limitation; alternative carriers can be a defense. |
| Core size 150-355 µm |
Claim 7, 32 |
Particle size engineering can avoid dependent claims. |
| Formulation % windows (apixaban ~0.1% w/w; carrier 9-11%; core 89-91%) |
Claims 9-12, 34-36 |
Product composition shifting can step outside these dependent ranges. |
| Capsule, sprinkle capsule |
Claims 13-15, 44-45 |
Presentation-specific; alternate dosage formats reduce dependency coverage. |
| Unit dose (0.1 mg; 0.2-0.4 mg ranges) |
Claims 16, 20, 24-27 |
Strength-specific; different strengths reduce dependent claim fit. |
| Method: disperse/dissolve in liquid carrier; food/beverage; neonates |
Claims 17-19, 37-39 |
Labeling and administration instructions become enforcement targets. |
| Solvent apixaban concentration below solubility limit |
Claim 30 |
Manufacturing-specific constraint; can separate similar products on process. |
How strong is the patent estate behind US 11,896,586: what competitors must clear?
Only the claim set you provided is available in this prompt. A complete “landscape” requires the patent’s family, priority filings, continuations, related use patents, and the Orange Book listing tied to an NDA/ANDA/BLA. Those elements are not present here, so no accurate multi-patent estate map can be produced.
What can be stated from the claim set alone is the likely blocking scope:
- Product form: particulate apixaban micro-dosing with a cellulose-type carrier on specific excipient cores.
- How it’s made: spray-layered dispersion, and in a key branch, using apixaban solvent concentration below its solubility limit.
- How it’s used: dispersing/dissolving in food/beverage for thromboembolic disorder treatment, including neonates.
- Presentation: capsule, specifically sprinkle capsule, at unit doses around 0.1 mg to 0.4 mg.
From a competitive standpoint, the highest-risk adoption paths are products that:
- use spray-layered apixaban onto excipient cores at ~0.1% w/w apixaban and ~9-11% carrier,
- package in sprinkle capsules with dosing instructions to mix into food/beverage,
- use HPMC/Hypromellose as the carrier,
- and/or mirror the solubility-limit spray process described in Claim 30.
What generic entry risks exist for apixaban sprinkle formulations under these claims?
Risk drivers that increase likelihood of capture by claims
- The product uses a treated core with surface-applied apixaban + polymer carrier.
- The formulation uses similar relative loadings (about 0.1% apixaban by weight, and around 9-11% carrier).
- The dosage form is a sprinkle capsule with similar per-capsule apixaban amounts.
- The label instructs mixing/dispersing into food/beverage for dosing, including in neonatal populations.
Risk mitigators that lower fit to dependent claims
- Different carrier (not HPMC/hypromellose) avoids Claim 6 dependent scope.
- Different core size avoids Claim 7 dependent scope.
- Different apixaban loading or different formulation percentages avoids dependent ranges (Claims 9-12 / 34-36).
- Different unit strengths avoid dependent unit dose claims (Claims 16, 24-27, 44-45).
- Different administration format (not dispersing/dissolving in a liquid carrier; not food/beverage) avoids dependent method claims (Claims 18-19 / 38-39).
- Different process window for spray solution concentration could target Claim 30’s solubility-limited process limitation.
Design-around matrix: how could a competitor avoid infringement while keeping a similar clinical concept?
| Design lever |
Changes |
Claims likely impacted |
| Use a different carrier polymer |
Replace HPMC/hypromellose with another binder |
Mainly Claim 6/related dependent scope; Claim 1 still potential if carrier is considered “carrier” broadly. |
| Change core substrate type |
Use a core not in the listed types |
Mainly dependent Claim 3/4/31; base Claim 1/30 may still capture if “core substrate” construed broadly. |
| Change core size |
Move outside 150-355 µm |
Claims 7/32 dependent scope. |
| Change apixaban loading |
Move outside 0.001%-0.20% w/w |
Claim 1/30 core limitation. This is the hardest to avoid if drug amount per core must remain consistent. |
| Change formulation percentages |
Shift apixaban/carrier/core into different bands |
Dependent Claims 9-12 / 34-36. |
| Change dosage form |
Use sachets, oral liquid, pellets in a different container |
Dependent capsule/sprinkle claims (13-16, 44-45). |
| Change administration instruction |
Avoid “dispersing and/or dissolving” into food/beverage |
Method dependent claims (18-19, 38-39). |
| Change spray manufacturing solvent concentration |
Use apixaban solvent concentration not constrained by solubility limit |
Key dependent/branch protection in Claim 30. |
Key takeaways
- US 11,896,586 protects a surface-layered apixaban treated core with 0.001% to 0.20% apixaban and a cellulose polymer carrier applied by spray-layered dispersion.
- The strongest commercial coverage is for sprinkle capsule formulations and dosing frameworks that mix/dispense into food or beverage, including for neonates.
- Dependent claim limitations create practical design-around handles: carrier identity (HPMC/hypromellose), core substrate type, core size (150-355 µm), formulation % windows, unit doses (0.1-0.4 mg), and a solubility-limited spray process.
- The most litigation-relevant manufacturing discriminator is the solvent apixaban concentration below solubility limit limitation in Claim 30.
FAQs
1) What is the minimum apixaban loading range covered for the treated core?
About 0.001% w/w to 0.20% w/w (Claims 1 and 30).
2) Do the claims require HPMC/hypromellose as the carrier?
Not in Claim 1/8/17 baseline language as provided, but dependent Claim 6 specifies hydroxypropylcellulose and/or hypromellose.
3) Are sprinkle capsules explicitly covered?
Yes. Claim 15 (and parallel Claims 44-45) cover a sprinkle capsule.
4) Does the patent cover administering apixaban by mixing into food or beverage?
Yes. Claims 18-19 (and corresponding Claims 38-39) cover a liquid carrier that is food or beverage and include neonates.
5) What extra manufacturing limitation distinguishes Claim 30 from the simpler treated-core branch?
Claim 30 adds a spray-layered dispersion process executed with apixaban solvent concentration below a solubility limit.
References
No citable external sources were provided in the prompt.
